Back to Journals » International Journal of Nanomedicine » Volume 9 » Issue 1

Poly(styrene)-b-poly(DL-lactide) copolymer-based nanoparticles for anticancer drug delivery

Authors Lee J, Kim JS, Cho H, Kim D

Received 20 February 2014

Accepted for publication 9 April 2014

Published 3 June 2014 Volume 2014:9(1) Pages 2803—2813

DOI https://doi.org/10.2147/IJN.S62806

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 6


Jae-Young Lee,1 Jung Sun Kim,2 Hyun-Jong Cho,3 Dae-Duk Kim1

1College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Republic of Korea; 2Division of Health Sciences, Dongseo University, Busan, Republic of Korea; 3College of Pharmacy, Kangwon National University, Chuncheon, Republic of Korea

Abstract: Poly(styrene)-b-poly(DL-lactide) (PS-PDLLA) copolymer-based nanoparticles (NPs) of a narrow size distribution, negative zeta potential, and spherical shape were fabricated for the delivery of docetaxel (DCT). The particle size was consistently maintained in serum for 24 hours and a sustained drug release pattern was observed for 10 days in the tested formulations. The cytotoxicity of the developed blank NPs was negligible in prostate cancer (PC-3) cells. Cellular uptake and distribution of the constructed NPs containing a hydrophobic fluorescent dye was monitored by confocal laser scanning microscopy (CLSM) for 24 hours. Anti-tumor efficacy of the PS-PDLLA/DCT NPs in PC-3 cells was significantly more potent than that of the group treated with commercially available DCT, Taxotere® (P<0.05). Blood biochemistry tests showed that no serious toxicity was observed with the blank NPs in the liver and kidney. In a pharmacokinetic study of DCT in rats, in vivo clearance of PS-PDLLA/DCT NPs decreased while the half-life in blood increased compared to the Taxotere-treated group (P<0.05). The PS-PDLLA NPs are expected to be a biocompatible and efficient nano-delivery system for anticancer drugs.

Keywords: docetaxel, prolonged blood circulation, prostate cancer


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]